We’re accepting orders by email. To place an order, email support@myfreedompeptides.com with the product, strength, and quantity you’d like.

For research use only. Not for human or veterinary use. Supplied as a lyophilized powder for laboratory research.

BPC-157 research spans more than three decades, but almost all of it is preclinical. BPC-157 (“Body Protection Compound-157”) is a synthetic 15-amino-acid peptide, GEPPPGKPADDAGLV, derived from a protein fragment found in human gastric juice [1][2]. A 2025 systematic review of BPC-157 studies included 36 studies, 35 of them preclinical [3]. A 2026 systematic review of human data found three small studies with 30 participants in total and rated the certainty of evidence very low [4]. BPC-157 is not FDA-approved for any use [1][3].

What is BPC-157? Sequence and structure

PropertyValue
BPC-157 sequenceGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV) [2]
Length15 residues (pentadecapeptide) [1]
Molecular formulaC₆₂H₉₈N₁₆O₂₂ (PubChem CID 108101)
Molecular weight~1419.5 g/mol (PubChem CID 108101)
CAS (as listed on the MFP certificate)137525-51-0
Form supplied by MFPSupplied as a lyophilized powder for laboratory research

Origin of BPC-157

BPC-157 is described as a partial sequence of “body protection compound”, a substance isolated from human gastric juice [5]. A 2026 pharmaceutics review notes the peptide’s unusual stability in gastric juice [2].

Mechanisms studied in BPC-157 research

Reviews of the preclinical literature report these pathways in cell and animal models:

These are findings from experimental models and do not establish effects in people.

BPC-157 studies by model type

Evidence typeWhat the literature containsKey limitation
In vitroTendon fibroblast outgrowth, survival and migration [5]Cell systems only
Animal (mostly rodent)Muscle, tendon, ligament, bone and gastrointestinal models [3][6]Relevance to people not established [3][4]
PharmacokineticsPreclinical plasma half-life under 30 minutes; hepatic metabolism, renal clearance [2][3]Human pharmacokinetics poorly characterized [2]
Human3 small studies, n = 30 total; poor methodological quality; certainty very low [4]No controlled trials; no completed Phase II trial [2]

BPC-157 clinical trials and regulatory status

MFP analytical data for BPC-157

FieldLot DPS-9628420
Testing laboratoryHorizon Analytical (report no. 1023760)
MethodUPLC/MS
Purity99.42% (specification >98%)
Quantity9.9 mg (specification 10 mg)
Endotoxin<0.05 EU/mL, Pass
Analysis date08/12/2026

Frequently asked questions

What is BPC-157?

BPC-157 is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a gastric-juice protein fragment and studied mainly in preclinical models [1][2].

What is the BPC-157 sequence?

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, abbreviated GEPPPGKPADDAGLV [2].

Are there BPC-157 clinical trials?

Human data are limited to three small studies rated very low certainty, and no completed Phase II trial has been reported [2][4].

Is BPC-157 FDA-approved?

No. It is not approved for any indication [1][3].

Research materials and certificates

References

  1. Józwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. doi:10.3390/ph18020185. PMID: 40005999
  2. Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026;18(5):625. doi:10.3390/pharmaceutics18050625. PMID: 42198317
  3. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. doi:10.1177/15563316251355551. PMID: 40756949
  4. Poolton JT, Minett J, Kazmi A. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026;92(3). doi:10.52628/92.3.15837. PMID: 42885452
  5. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. doi:10.1152/japplphysiol.00945.2010. PMID: 21030672
  6. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972-1989. doi:10.2174/1381612824666180712110447. PMID: 29998800
  7. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. doi:10.1007/s12178-025-09990-7. PMID: 40789979
  8. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2). Content current as of 04/22/2026. fda.gov

Research-use-only disclaimer: All products from My Freedom Peptides are supplied as a lyophilized powder for laboratory research. They are for research use only and not for human or veterinary use. My Freedom Peptides LLC is a chemical supplier. It is not a 503A compounding pharmacy or a 503B outsourcing facility. These statements have not been evaluated by the Food and Drug Administration. Products are not intended to diagnose, treat, cure, or prevent any disease.